| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18834621 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 100 journal articles in the PubMed database | Email to a friend | | |
| Darcy KM, Brady WE, McBroom JW, et al.
Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. [JOURNAL ARTICLE]
Gynecol Oncol 2008 Sep 30.
Abstract | Full Citation | Find Related Articles | | Krivak TC, Darcy KM, Tian C, et al.
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. [Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
J Clin Oncol 2008 Jul 20; 26(21):3598-606.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Holloway RW, Mehta RS, Finkler NJ, et al.
Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. [Clinical Trial, Journal Article]
Gynecol Oncol 2002 Oct; 87(1):8-16.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Secord AA, Darcy KM, Hutson A, et al.
Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study. [JOURNAL ARTICLE]
Gynecol Oncol 2007 May 2.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Schaebler DL, Schilder RJ, Young RC
Gynecological malignancies. [Journal Article, Review]
Cancer Chemother Biol Response Modif 1996.:564-91.
Abstract | Full Citation | Find Related Articles | | Levesque MA, Katsaros D, Massobrio M, et al.
Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. [Journal Article]
Clin Cancer Res 2000 Aug; 6(8):3260-70.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Secord AA, Lee PS, Darcy KM, et al.
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. [Journal Article]
Gynecol Oncol 2006 Jun; 101(3):390-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Darcy KM, Tian C, Reed E
A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. [Journal Article, Research Support, N.I.H., Extramural]
Cancer Res 2007 May 1; 67(9):4474-81.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | du Bois A, Lück HJ, Meier W, et al.
Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. [Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial]
Semin Oncol 1997 Aug; 24(4 Suppl 11):S11-28-S11-33.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
